Citations

Clear

5212 citation(s) found for "Wang, Li-Ju".

Alpha‐1 Antitrypsin Deficiency Liver Disease, Mutational Homogeneity Modulated by Epigenetic Heterogeneity With Links to Obesity
Wang, Liguo , Marek, George , Hlady, Ryan A. , Wagner, Ryan T. , Zhao, Xia , Clark, Virginia , Fan, Alex Xiu‐Cheng, Liu, Chen , Robertson, Keith D. , Robertson, Keith D , Wang, Liguo , Liu, Chen , Brantly, Mark

Mayo Clinic

Hepatology | January 25, 2019 | Volume: 70 | Issue: 1 | Pages: 51-66

10.1002/hep.30526 | PMID 30681738 Get It

Alpha‐1 antitrypsin deficiency (AATD) liver disease is characterized by marked heterogeneity in presentation and progression, despite a common underlying gene mutation, strongly suggesting the involvement of other genetic and/or epigenetic modifiers. Variation in clinical phenotype has added to the challenge of detection, diagnosis, and testing of new therapies in patients with AATD. We examined the contribution of DNA methylation (5‐methylcytosine [5mC]) to AATD liver disease heterogeneity because 5mC responds to environmental and genetic cues and its deregulation is a major driver of liver disease. Using liver biopsies from adults with early‐stage AATD and the ZZ genotype, genome‐wide 5mC patterns were interrogated. We compared DNA methylation among patients with early AATD, and among patients with normal liver, cirrhosis, and hepatocellular carcinoma derived from multiple etiologic exposures, and linked patient clinical/demographic features. Global analysis revealed significant genomic hypomethylation in AATD liver–impacting genes related to liver cancer, cell cycle, and fibrosis, as well as key regulatory molecules influencing growth, migration, and immune function. Further analysis indicated that 5mC changes are localized, with hypermethylation occurring within a background of genome‐wide 5mC loss and with patients with AATD manifesting distinct epigenetic landscapes despite their mutational homogeneity. By integrating clinical data with 5mC landscapes, we observed that CpGs differentially methylated among patients with AATD disease are linked to hallmark clinical features of AATD (e.g., hepatocyte degeneration and polymer accumulation) and further reveal links to well‐known sex‐specific effects of liver disease progression. Conclusion: Our data reveal molecular epigenetic signatures within this mutationally homogeneous group that point to ways to stratify patients for liver disease risk.
Generic and Brand-Name Thyroid Hormone Drug Use Among Commercially Insured and Medicare Beneficiaries, 2007 Through 2016
Ross, Joseph S. , Rohde, Stefanie , Sangaralingham, Lindsey R. , Brito, Juan P. , Choi, Lauren , Graham, David J. , Jenkins, Marjorie , Mendoza, Martín, Qiang, Yandong, Wang, Zhong , Wu, Yute, Shah, Nilay D. , Sangaralingham, Lindsey, Yao, Xiaoxi , Ross, Joseph S , Brito, Juan P , Dutcher, Sarah K. , Lipska, Kasia J.

Mayo Clinic

The Journal of Clinical Endocrinology & Metabolism | January 25, 2019 | Volume: 104 | Issue: 6 | Pages: 2305-2314

10.1210/jc.2018-02197 | PMID 30690529 Get It

Stiffness distribution in the ablated zone after radiofrequency ablation for liver: An ex-vivo study with a tissue elastometer
Li, Xiao‐Long , Liu, Bo-Ji, Chen, Shigao , Li, Dandan , Xu, Hui‐Xiong , Guo, Le‐Hang , Wang, Dan Michelle

Mayo Clinic

Clinical Hemorheology and Microcirculation | January 25, 2019 | Volume: 72 | Issue: 2 | Pages: 151-160

10.3233/ch-180404 | PMID 30689559 Get It

DOP35 Innate immune dysregulation, detectable up to 6 years before the diagnosis of Crohn’s disease, is significantly amplified in patients with a complicated phenotype
Petralia, Francesca , Sato, Takaya , Li, X-j, Wang, Ping , Telesco, Shannon, Porter, Chad, Laird, Renée M. , Gutiérrez, Ramiro L. , Princen, Fred, Plevy, SE, Strauss, Richard E. , Riddle, Mark S. , Colombel, J F, Group, PREDICTS (PRoteomic Evaluation and Discovery in an IBD Cohort of Tri-service Subjects) Study, Choung, Rok Seon , Torres, Joana , Strauss, R, Murray, Joseph A. , Group, PREDICTS (PRoteomic Evaluation and Discovery in an IBD Cohort of Tri-service Subjects) Study

Mayo Clinic

Journal of Crohn's and Colitis | January 25, 2019 | Volume: 13 | Issue: Supplement_1 | Pages: S045-S046

10.1093/ecco-jcc/jjy222.069 Get It

P479 Analysis of haematological changes in tofacitinib-treated patients with ulcerative colitis across Phase 3 induction and maintenance studies
Lichtenstein, Gary R. , Soonasra, Arif, Nduaka, Chudi, Wang, L, Lawendy, Nervin, Chan, Geoffrey , Moore, Gregory , Kwok, Kenneth , Su, C, Loftus, Edward V.

Mayo Clinic

Journal of Crohn's and Colitis | January 25, 2019 | Volume: 13 | Issue: Supplement_1 | Pages: S351-S352

10.1093/ecco-jcc/jjy222.603 Get It

Personalized management in functional gastrointestinal disorders based on genomics: hope at last or just feigned praise?
Camilleri, Michael , Wang, Xiao Jing (Iris), Camilleri, M , Wang, Xiao‐Jing

Mayo Clinic

Therapeutic Advances in Gastroenterology | January 24, 2019 | Volume: 12 | Issue: No issue available | Pages: No page available

10.1177/1756283x18822791 | PMID 30719078 Get It

Therapeutic Remodeling of the Tumor Microenvironment Enhances Nanoparticle Delivery
Chen, Yuanxin , Yuan, Hengfeng , Yang, Zhaogang , Roemeling, Christina A. Von , Qie, Yaqing, Hai, Zhao , Wang, Yifan , Jiang, Wen , Kim, Betty Y.S. , Liu, Xiujie, von Roemeling, Christina A, Zhao, Hai, Jiang, Wen , Kim, Betty Y S , von Roemeling, Christina A , Liu, Xiujie

Mayo Clinic

Advanced Science | January 24, 2019 | Volume: 6 | Issue: 5 | Pages: No page available

10.1002/advs.201802070 | PMID 30886813 Get It

AbstractA major challenge in the development of cancer nanomedicine is the inability for nanomaterials to efficiently penetrate and deliver therapeutic agents into solid tumors. Previous studies have shown that tumor vasculature and extracellular matrix regulate the transvascular and interstitial transport of nanoparticles, both critical for successfully delivering nanomedicine into solid tumors. Within the malignant tumor microenvironment, blood vessels are morphologically abnormal and functionally exhibit substantial permeability. Furthermore, the tumor extracellular matrix (ECM), unlike that of the normal tissue parenchyma, is densely packed with collagen. These pathophysiological properties greatly impede intratumoral delivery of nanomaterials. By using an antivascular endothelial growth factor receptor antibody, DC101, and an antitransforming growth factor β1 (TGF‐β1) antibody, normalization of the tumor vasculature and ECM is achieved, respectively, in a syngeneic murine glioma model. This normalization effect results in a more organized vascular network, improves tissue perfusion, and reduces collagen density, all of which contribute to enhanced nanoparticle delivery and distribution within tumors. These findings suggest that combined vascular and ECM normalization strategies can be used to remodel the tumor microenvironment and improve nanomedicine delivery into solid tumors, which has significant implications for developing more effective combinational therapeutic strategies using cancer nanomedicine.
Reply to Lutz-Bonengel et al.: Biparental mtDNA transmission is unlikely to be the result of nuclear mitochondrial DNA segments
Luo, Shiyu , Valencia, C. Alexander , Lee, Ni‐Chung , Slone, Jesse , Gui, Baoheng , Wang, Xinjian , Dell, Sarah, Brown, Jenice, Chen, Stella Maris, Hwu, Wuh‐Liang , Fan, Pi‐Chuan , Wong, Lee‐Jun C. , Huang, Taosheng , Li, Zhuo , Zhang, Jinglan , Li, Zhuo , Chien, Yin-Hsiu , Atwal, Paldeep S

Mayo Clinic

Proceedings of the National Academy of Sciences | January 23, 2019 | Volume: 116 | Issue: 6 | Pages: 1823-1824

10.1073/pnas.1821357116 | PMID 30674682 Get It

Sleeping Beauty Insertional Mutagenesis Reveals Important Genetic Drivers of Central Nervous System Embryonal Tumors
Beckmann, Pauline J. , Larsson, Alex T. , Ostergaard, Jason, Wagner, Sandra, Rahrmann, Eric P. , Shamsan, Ghaidan A. , Otto, George M. , Williams, Rory L. , Wang, Jun , Lee, Catherine , Tschida, Barbara R. , Das, Paramita , Dubuc, Adrian M. , Moriarity, Branden S. , Picard, Daniel , Wu, Xiaochong , Rosemarie, Quincy , Krebs, Ryan D., Molan, Amy M. , Demer, Addison M. , Frees, Michelle M. , Rizzardi, Anthony E., Schmechel, Stephen C. , Jenkins, Robert B. , Wechsler‐Reya, Robert J. , Odde, David J. , Taylor, Michael D. , Sarver, Aaron L. , Largaespada, David A. , Rahrmann, Eric P , Shamsan, Ghaidan A , Williams, Rory L , Picard, Daniel , Rosemarie, Quincy , Odde, David J , Larson, Jon D. , Wagner, Sandra, Tschida, Barbara R , Rodríguez, Fausto J. , Krebs, Ryan D., Eberhart, Charles G. , Huang, Annie , Largaespada, David A.

Mayo Clinic

Cancer Research | January 23, 2019 | Volume: 79 | Issue: 5 | Pages: 905-917

10.1158/0008-5472.can-18-1261 | PMID 30674530 Get It

Abstract Medulloblastoma and central nervous system primitive neuroectodermal tumors (CNS-PNET) are aggressive, poorly differentiated brain tumors with limited effective therapies. Using Sleeping Beauty (SB) transposon mutagenesis, we identified novel genetic drivers of medulloblastoma and CNS-PNET. Cross-species gene expression analyses classified SB-driven tumors into distinct medulloblastoma and CNS-PNET subgroups, indicating they resemble human Sonic hedgehog and group 3 and 4 medulloblastoma and CNS neuroblastoma with FOXR2 activation. This represents the first genetically induced mouse model of CNS-PNET and a rare model of group 3 and 4 medulloblastoma. We identified several putative proto-oncogenes including Arhgap36, Megf10, and Foxr2. Genetic manipulation of these genes demonstrated a robust impact on tumorigenesis in vitro and in vivo. We also determined that FOXR2 interacts with N-MYC, increases C-MYC protein stability, and activates FAK/SRC signaling. Altogether, our study identified several promising therapeutic targets in medulloblastoma and CNS-PNET. Significance: A transposon-induced mouse model identifies several novel genetic drivers and potential therapeutic targets in medulloblastoma and CNS-PNET.